COVID-19 VaccinE Response in Rheumatology Patients

PHASE4CompletedINTERVENTIONAL
Enrollment

841

Participants

Timeline

Start Date

November 15, 2021

Primary Completion Date

April 4, 2024

Study Completion Date

May 28, 2024

Conditions
Rheumatoid ArthritisPsoriatic ArthritisSpondylarthritis
Interventions
DRUG

Upadacitinib

Hold UPA x 2 weeks at time of COVID booster

DRUG

Abatacept

Hold SQ ABA x 2 weeks at time of COVID booster

DRUG

Secukinumab

Hold SEC x 2 weeks at time of COVID booster

DRUG

Tofacitinib

Hold TOF x 2 weeks at time of COVID booster

DRUG

TNF Inhibitor

Hold SQ TNFi x 2 weeks at time of COVID booster

DRUG

Canakinumab Injection

Hold CAN TNFi x 2 weeks at time of COVID booster

DRUG

Baricitinib

Hold BAR x 2 weeks at time of COVID booster

DRUG

Ixekizumab

Hold IXE x 2 weeks at time of COVID booster

Trial Locations (8)

19104

University of Pennsylvania Medical Center, Philadelphia

35244

Illumination Health/Bendcare, Hoover

Rheumatology Care Center, Hoover

35294

University of Alabama at Birmingham, Birmingham

68198

University of Nebraska Medical Center, Omaha

75231

Metroplex Clinical Research Center, Dallas

85032

Arizona Arthritis & Rheumatology Research, PLLC, Phoenix

90211

Attune Health, Beverly Hills

All Listed Sponsors
collaborator

University of Alabama at Birmingham

OTHER

collaborator

University of Nebraska

OTHER

collaborator

University of Pennsylvania

OTHER

collaborator

AbbVie

INDUSTRY

collaborator

Bristol-Myers Squibb

INDUSTRY

collaborator

Novartis

INDUSTRY

collaborator

Eli Lilly and Company

INDUSTRY

collaborator

Pfizer

INDUSTRY

collaborator

Illumination Health

NETWORK

lead

Jeffrey Curtis

OTHER

NCT05080218 - COVID-19 VaccinE Response in Rheumatology Patients | Biotech Hunter | Biotech Hunter